Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

PTC Therapeutics Inc (NASDAQ:PTCT)

14.01
Delayed Data
As of Sep 30
 +2.45 / +21.19%
Today’s Change
5.27
Today|||52-Week Range
35.76
-56.76%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$395.9M

Company Description

PTC Therapeutics, Inc. engages in the discovery, development, and commercialization of orally administered, small molecule therapeutics targeting an area of RNA biology. Its preclinical and discovery programs are focused on the development of new treatments for multiple therapeutic areas, including neuromuscular disease, oncology and infectious disease. It product, candidate ataluren, is used for the treatment of patients with genetic disorders that arise from a type of genetic mutation known as a nonsense mutation. The company was founded by Allan S. Jacobson and Stuart W. Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ.

Contact Information

PTC Therapeutics, Inc.
100 Corporate Court
South Plainfield New Jersey 07080-2449
P:(908) 222-7000
Investor Relations:
(908) 912-9167

Employees

Shareholders

Mutual fund holders48.63%
Other institutional36.78%
Individual stakeholders23.79%

Top Executives

Stuart W. PeltzChief Executive Officer & Class I Director
Neil Gregory AlmsteadExecutive VP-Research, Operations & Technology
Shane William Charles KovacsCFO & Head-Corporate Development
Tuyen OngChief Medical Officer
Mark Elliott BouldingSecretary, Chief Legal Officer & Executive VP